Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL
- 348 Downloads
Selective IgA deficiency (SIgAD) is the most common primary immunodeficiency with a prevalence of 1/600 in the general population. Any targeted health-related quality of life (HRQL) study of adults with SIgAD has never been presented. The objectives of the study were to compare HRQL between SIgAD adults and randomly selected age- and gender-matched population controls, and to identify risk factors for poor HRQL.
Thirty-two SIgAD individuals and 63 controls answered three questionnaires (clinical data, Short Form-36 Health Survey (SF-36), infection-related HRQL) at baseline before undergoing medical/dental examinations and laboratory assessments. HRQL in SIgAD was re-evaluated after 6 and 12 months.
Baseline: Selective IgA deficiency individuals reported significantly increased fear of contracting infections (p < 0.01). Those scoring high on fear also perceived significantly poorer physical health (p < 0.01). SF-36 results indicated that SIgAD individuals perceived poorer HRQL, although this was not statistically significant. Follow-up: Compared with SF-36 responses at baseline, SIgAD individuals reported significantly more pain (p < 0.01) at 6 months, poorer general health (p < 0.05) and summarised physical HRQL (p < 0.01) at 6 and 12 months and decreased vitality at 12 months. The summarised mental scale remained stable over time. Risk factors for poor HRQL: The number of antibiotic treatments during the previous year (p < 0.001), number of daily medications (p < 0.01), allergic rhinoconjunctivitis (p < 0.05), chronic musculoskeletal symptoms at least every week (p < 0.05) and anxiety and/or insomnia (p < 0.05) were identified as independent risk factors for poor HRQL.
The study highlights the importance of identifying and thoroughly evaluating, educating and following up individuals with SIgAD, as their HRQL may be negatively affected due to health problems possible to prevent and treat.
KeywordsPrimary immunodeficiency IgA deficiency Quality of life SF-36 Patient-reported outcomes Risk factors
Selective IgA deficiency
Health-related quality of life
Short Form-36 Health Survey
Common variable immunodeficiency
Physical component summary score
Mental component summary score
Body mass index
We are grateful to all the individuals participating in the study, and to Hilary Hocking, Östersund, Sweden, for language revision. This study was supported by the Landspitali University Hospital Research Fund, the Icelandic Research Fund, Karolinska Institutet (KI Fonder), Stockholm, Sweden, and Division of Research and Development, Primary Care, County Council of Uppsala, Sweden.
Conflict of interest
No conflict of interest is reported for any of the authors.
- 2.Al-Herz, W., Bousfiha, A., Casanova, J.-L., Chapel, H., Conley, M. E., Cunningham-Rundles, C., et al. (2011). Primary immunodeficiency diseases: An update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency. Frontiers in Immunology, 2(54). doi: 10.3389/fimmu.2011.00054.
- 3.Smith, C. I. E., Ochs, H. D., & Puck, J. M. (2007). Genetically determined immunodeficiency diseases: A perspective. In H. D. Ochs, C. I. Edward Smith, & J. M. Puck (Eds.), Primary Immunodeficiency Diseases: A Molecular and Genetic Approach (2nd ed., pp. 3–15). New York: Oxford University Press.Google Scholar
- 4.(2013). About PI Primary Immunodeficiency (PI) affects as many as 1 million Americans and 10 million worldwide. Yet, it is just beginning to receive widespread attention. Info4PI.org Primary Immunodeficiency Resource center. Available at: http://www.info4pi.org/aboutPI/index.cfm?section=aboutPI&CFID=807672&CFTOKEN=165ae47bb16954ef-1CD0322C-0C55-E9FC-E4955D9A107D7A85. Accessed 20 Feb 15th 2013.
- 5.EU PID Consensus Document. (2013). Available at: http://www.esid.org/home.php?sub=2&id=93. Accessed 20 Feb 2013.
- 6.(2010). Deficient diagnosis. Parliament Magazine (pp. 24–25). Available at: http://www.info4pi.org/Documents/Publications/Acticle%20Parliament%20magazine_20100506_110013.pdf. Accessed 20 Feb 2013.
- 7.Fayers, P. M., & Machim, D. (2000). Quality of Life, assessment, analysis and interpretation. West Sussex: John Wiley & Sons Ltd.Google Scholar
- 10.Schipper, H., Clinch, J. J., & Olweny, C. L. M. (1996). Quality of life studies: Definitions and conceptual issues. In B. Spilker (Ed.), Quality of life and pharmacoeconomics in clinical trials (2nd ed., pp. 11–23). Philadelphia: Lippincott-Raven.Google Scholar
- 12.Gardulf, A., Björvell, H., Gustafson, R., Hammarström, L., & Smith, C. I. E. (1993). The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clinical and Experimental Immunology, 92(2), 200–204.PubMedCentralPubMedCrossRefGoogle Scholar
- 16.Mozaffari, H., Pourpak, Z., Pourseyed, S., Moin, M., Farhoodi, A., Aghamohammadi, A., et al. (2006). Health-related quality of life in primary immune deficient patients. Iranian Journal of Allergy, Asthma and Immunology, 5(1), 23–27.Google Scholar
- 17.Winkelstein, J. A., Conley, M. E., James, C., Howard, V., & Boyle, J. (2008). Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore), 87(5), 253–258.CrossRefGoogle Scholar
- 18.Aghamohammadi, A., Montazeri, A., Abolhassani, H., Saroukhani, S., Pourjabbar, S., Tavassoli, M., et al. (2011). Health-related quality of life in primary antibody deficiency. Iranian Journal of Allergy, Asthma and Immunology, 10(1), 47–51.Google Scholar
- 19.Berger, M., Murphy, E., Riley, P., & Bergman, G. E. (2010). Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. Southern Medical Journal, 103(9), 856–863.PubMedCrossRefGoogle Scholar
- 20.Hoffmann, F., Grimbacher, B., Thiel, J., Peter, H. H., & Belohradsky, B. H. (2010). Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. European Journal of Medical Research, 15(6), 238–245.PubMedCentralPubMedGoogle Scholar
- 22.Borte, M., Bernatowska, E., Ochs, H. D., Roifman, C. M., & The Vivaglobin Study Group. (2011). Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clinical and Experimental Immunology, 164(3), 357–364.PubMedCentralPubMedCrossRefGoogle Scholar
- 23.Modell, V., Gee, B., Lewis, D. B., Orange, J. S., Roifman, C. M., Routes, J. M., et al. (2011). Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: An updated report from the Jeffrey Modell Foundation. Immunologic Research, 51(1), 61–70.PubMedCrossRefGoogle Scholar
- 26.Gardulf, A., Borte, M., Ochs, H. D., Nicolay, U., & Group, V. C. S. Vivaglobin Clinical Study Group. (2008). Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clinical Immunology, 126(1), 81–88.PubMedCrossRefGoogle Scholar
- 27.Gardulf, A., Nicolay, U., Math, D., Asensio, O., Bernatowska, E., Böck, A., et al. (2004). Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. The Journal of Allergy and Clinical Immunology, 114(4), 936–942.PubMedCrossRefGoogle Scholar
- 28.Nicolay, U., Kiessling, P., Berger, M., Gupta, S., Yel, L., Roifman, C. M., et al. (2006). Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. Journal of Clinical Immunology, 26(1), 65–72.PubMedCrossRefGoogle Scholar
- 29.Hammarström, L., & Edvard Smith, C. I. (2007). Genetic approach to common variable immunodeficiency and IgA deficiency. In H. D. Ochs, C. I. Edward Smith, & J. M. Puck (Eds.), Primary immunodeficiency diseases: A molecular and genetic approach (2nd ed., pp. 313–325). New York: Oxford University Press.Google Scholar
- 30.(2013). Diagnostic criteria for PID. European Society for Immunodeficiencies. Available at: http://www.esid.org./clinical-diagnostic-criteria-for-pid-73-0#Q7www.esid.org. Accessed 20 Feb 2013.Google Scholar
- 42.Gardulf, A. (1994). Rapid subcutaneous immunoglobulin replacement therapy in patients with primary antibody deficiency: Aspects of effectiveness safety, home-therapy, quality of life and costs. PhD-thesis, Karolinska Institutet, Stockholm. ISBN no 91-628-1403-6.Google Scholar
- 43.Ware, J. E., Jr., Snow, K. K., Kosinski, M., Gandek, B. (1993, 2000). SF-36 ® Health Survey: Manual and interpretation guide. Lincoln, RI: QualityMetric Incorporated.Google Scholar
- 47.Gardulf, A., Hansen, S., Elnerson, K., Ericson, E., Fust, R., Hagstedt, C., et al. (2007). In Swedish. [The SwePID Study; To live with a primary immunodeficiency. Report regarding adults]. Available at http://ki.se/ki/jsp/polopoly.jsp?d=16775&l=en. Stockholm: Karolinska Institutet.
- 52.Leong, K. P., Yeak, S. C., Saurajen, A. S., Mok, P. K., Earnest, A., Siow, J. K., et al. (2005). Why generic and disease-specific quality-of-life instruments should be used together for the evaluation of patients with persistent allergic rhinitis. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology, 35(3), 288–298.CrossRefGoogle Scholar